Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 15/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 15/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 14/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 14/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.64 |
| ▸ | TET3 | O43151 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.57 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.57 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.57 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310001 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL16806728 | 0.86 | HDAC1 (0.76) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL7008414 | 0.80 | HDAC1 (0.66) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL309994 | 0.78 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL309995 | 0.78 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL18085938 | 0.77 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL16806774 | 0.77 | HDAC1 (0.71) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL16806952 | 0.76 | HDAC1 (0.70) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL8236096 | 0.76 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL16806967 | 0.76 | HDAC1 (0.61) | HDAC1HDAC3HDAC2HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | claimed |
| EP-1870399-A1 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2007-12-26 | — | — | EP | claimed |
| EP-1318980-B1 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-10-31 | — | — | EP | claimed |
| US-20060189674-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2006-08-24 | — | — | US | claimed |
| US-20050227300-A1 | Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors | ATADJA PETER W | 2005-10-13 | — | — | US | claimed |
| US-20050085507-A1 | p-phenylethenyl hydroxamates; anticarcinogenic, antitumor, antiproliferative agents; regulating p21 promoter; improved stability | SECURA BIO, INC. | 2005-04-21 | — | — | US | claimed |
| EP-1456664-A1 | USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS | Novartis AG (CH) | 2004-09-15 | — | — | EP | claimed |
| US-20040024067-A1 | Deacetylase inhibitors | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2004-02-05 | — | — | US | claimed |
| EP-1318980-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2003-06-18 | — | — | EP | claimed |
| WO-2003048774-A1 | USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2003-06-12 | — | — | WO | claimed |
| US-20030018062-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2003-01-23 | — | — | US | claimed |
| WO-2002022577-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | claimed |
| US-8883842-B2 | Use of HDAC inhibitors for the treatment of myeloma | NOVARTIS AG (CH) | 2014-11-11 | — | — | US | disclosed |
| US-20120029047-A1 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF BONE DESTRUCTION | SECURA BIO, INC. | 2012-02-02 | — | — | US | disclosed |
| US-8093220-B2 | Combination of an HDAC inhibitor and an antimetabolite | NOVARTIS AG (CH) | 2012-01-10 | — | — | US | disclosed |
| US-20110288144-A1 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA | NOVARTIS AG (CH) | 2011-11-24 | — | — | US | disclosed |
| WO-2003048774-A1 | USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2003-06-12 | — | — | WO | disclosed |
| US-6552065-B2 | Antiproliferative agents | NOVARTIS AG (CH) | 2003-04-22 | — | — | US | disclosed |
| US-20030018062-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2002022577-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085507-A1 | p-phenylethenyl hydroxamates; anticarcinogenic, antitumor, antiproliferative agents; regulating p21 promoter; improved stability | TP53, CDKN1A, HDAC1 | HDAC1 3/4885HDAC3 16/4885HDAC2 18/4885 |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC3 2/4885HDAC2 9/4885 |
| US-20040024067-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC3 2/4885HDAC2 9/4885 |
| US-20120029047-A1 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF BONE DESTRUCTION | HDAC5, HDAC4, HDAC1 | HDAC1 3/4885HDAC3 8/4885HDAC2 6/4885 |
| US-20110288144-A1 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA | HDAC5, HDAC1, HDAC9 | HDAC1 2/4885HDAC3 6/4885HDAC2 5/4885 |
| US-20060189674-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC3 2/4885HDAC2 9/4885 |
| US-20030018062-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC3 2/4885HDAC2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.